Earnings summaries and quarterly performance for APTARGROUP.
Executive leadership at APTARGROUP.
Stephan B. Tanda
Detailed
President and Chief Executive Officer
CEO
Gael Touya
Detailed
President of Aptar Pharma
Hedi Tlili
Detailed
President of Aptar Closures
Kimberly Y. Chainey
Detailed
Executive Vice President, Chief Legal Officer and Secretary
Marc Prieur
Detailed
President of Aptar Beauty
Vanessa Kanu
Detailed
Executive Vice President and Chief Financial Officer
Xiangwei Gong
Detailed
Executive Vice President, Strategic Group Development and President of Aptar Asia
Board of directors at APTARGROUP.
B. Craig Owens
Detailed
Director
Candace Matthews
Detailed
Chair of the Board
George L. Fotiades
Detailed
Director
Giovanna Kampouri Monnas
Detailed
Director
Isabel Marey-Semper
Detailed
Director
Julie Xing
Detailed
Director
Matt Trerotola
Detailed
Director
Ralf K. Wunderlich
Detailed
Director
Sarah Glickman
Detailed
Director
Research analysts who have asked questions during APTARGROUP earnings calls.
Daniel Rizzo
Jefferies
4 questions for ATR
Also covers: APD, AZZ, CBT +15 more
Gabe Hajde
Wells Fargo & Company
4 questions for ATR
Also covers: AMBP, AMCR, CCK +11 more
George Staphos
Bank of America
4 questions for ATR
Also covers: AMBP, AMCR, AVY +18 more
Ghansham Panjabi
Robert W. Baird & Co.
4 questions for ATR
Also covers: AMCR, AVNT, AVY +20 more
Matthew Larew
William Blair & Company
3 questions for ATR
Also covers: AMED, DNA, MASS +10 more
Matthew Roberts
Raymond James
3 questions for ATR
Also covers: AMCR, AVY, GEF +4 more
Recent press releases and 8-K filings for ATR.
AptarGroup, Inc. issues 4.750% Senior Notes due 2031
ATR
Debt Issuance
- AptarGroup, Inc. completed an underwritten public offering of $600 million aggregate principal amount of its 4.750% Senior Notes due 2031 on November 20, 2025.
- The Notes mature on March 30, 2031, and bear interest at an annual rate of 4.750%, payable semi-annually in arrears on March 30 and September 30 of each year, beginning March 30, 2026.
- The Company may redeem the Notes at its option prior to February 28, 2031 (the "Par Call Date"), at a make-whole redemption price, and at 100% of the principal amount on or after the Par Call Date.
- These Notes are unsecured obligations of the Company and rank equally in right of payment with all of the Company’s other existing and future senior unsecured indebtedness.
Nov 20, 2025, 9:30 PM
AptarGroup highlights strong pharma business growth and capital allocation strategy at Jefferies Conference
ATR
Dividends
Share Buyback
New Projects/Investments
- AptarGroup's pharma business is a key driver, contributing almost 70% of EBITDA, focusing on proprietary drug delivery devices. This segment has seen strong performance with top-line growth of 7%-11% and adjusted EBITDA growth of 26% in recent years, with profitability in the 32%-36% EBITDA range.
- The company has a strong track record of capital returns, including 32 years of annually increasing dividends and a recent 7% dividend increase.
- Capital deployment prioritizes the high-returning pharma business. AptarGroup has returned $8 billion in dividends and $6 billion in share repurchases over the last seven years.
- AptarGroup has leaned into share repurchases, having executed approximately $190 million or 1.3 million shares year-to-date through Q3, and plans to exhaust the remaining $273 million in authorized buybacks.
- The injectable segment, boosted by GLP-1, is a significant growth driver within pharma, expected to reach 20% of pharma injectables or more. CapEx is anticipated to remain steady-state, with no major new site investments planned for the coming years.
Nov 19, 2025, 12:00 PM
AptarGroup Highlights Pharma Growth and Capital Allocation at Jefferies Conference
ATR
Dividends
Share Buyback
New Projects/Investments
Revenue Acceleration/Inflection
- AptarGroup's pharma business is the primary profit driver, contributing almost 70% of EBITDA and achieving 7%-11% top-line growth and 26% adjusted EBITDA growth in recent years.
- The company has a strong track record of 32 years of annually increasing dividends and recently announced a 7% dividend increase, with a payout ratio at the lower end of its 30%-40% target.
- Aptar is actively engaged in share repurchases, having bought back $190 million or 1.3 million shares year-to-date through Q3, with $273 million remaining in board-authorized funds.
- Capital deployment prioritizes the pharma business due to its high returns and rapid growth, with the injectables business (fueled by GLP-1) being a significant growth driver, though proprietary nasal delivery remains the larger and more profitable segment.
Nov 19, 2025, 12:00 PM
AptarGroup Discusses Pharma Business Growth and Capital Allocation at Jefferies Conference
ATR
Dividends
Share Buyback
New Projects/Investments
- AptarGroup's pharma business is the primary profit engine, contributing almost 70% of EBITDA, driven by proprietary drug delivery systems for chronic diseases, with 7%-11% top-line growth in recent years and 32%-36% EBITDA profitability.
- The company has a 32-year track record of annually increasing dividends, recently announcing a 7% increase, and prioritizes capital deployment towards its high-returning pharma business.
- AptarGroup's injectables business, particularly GLP-1, is a significant growth driver, though nasal delivery remains the largest and most profitable pharma segment.
- Management believes the stock price reaction to the Narcan pullback is "overdone" and has been actively executing share repurchases, with $190 million (1.3 million shares) bought back year-to-date to Q3 and $273 million remaining in authorization.
- Future capital expenditure is expected to be steady state, focusing on additional equipment and capacity within existing facilities rather than large new site constructions.
Nov 19, 2025, 12:00 PM
AptarGroup Reports Q3 2025 Results, Raises Dividend, and Provides Q4 Outlook
ATR
Earnings
Guidance Update
Share Buyback
- AptarGroup reported a 6% increase in reported sales and 1% core sales growth for Q3 2025, with adjusted earnings per share (EPS) rising 4% year-over-year to $1.62. Consolidated adjusted EBITDA margins improved by 30 basis points to 23.2%.
- The Pharma segment's core sales increased 2%, primarily driven by an 18% rise in injectables, contributing to a 120 basis point improvement in its adjusted EBITDA margin to 37.2%. Beauty core sales were flat, and Closures core sales decreased 1%.
- The company increased its quarterly dividend by nearly 7% to $0.48 per share and has repurchased $190 million in shares year-to-date, with the remaining $270 million of authorization expected to be utilized over the next couple of quarters.
- For Q4 2025, adjusted EPS is projected to be between $1.20 and $1.28 per share. The company anticipates a significant headwind in emergency medicine, expecting 2026 revenues from this segment to be approximately 35% lower than 2025 due to elevated customer inventory levels.
Oct 31, 2025, 1:00 PM
Aptar Reports Solid Q3 2025 Results with Sales Growth and Increased EPS
ATR
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Aptar delivered Q3 2025 reported sales of $961 million, marking a 6% reported sales growth and 1% core sales growth.
- Q3 2025 Reported Earnings Per Share (EPS) was $1.92, representing a 30% increase, while Adjusted EPS grew 4% to $1.62.
- The Pharma segment demonstrated strong performance, with injectables core sales increasing 18% and its Adjusted EBITDA Margin improving by 120 basis points.
- For the full year-to-date 2025, reported sales reached $2,814 million and reported EPS was $4.75.
- Aptar projects Q4 2025 Adjusted EPS to be in the range of $1.20 to $1.28.
Oct 31, 2025, 1:00 PM
AptarGroup Reports Strong Q3 2025 Results and Provides Q4 Outlook
ATR
Earnings
Guidance Update
Share Buyback
- AptarGroup reported a 6% increase in sales to $961 million and a 1% increase in core sales for the third quarter of 2025. Reported net income grew 28% to $128 million, with reported earnings per share increasing 30% to $1.92. Adjusted earnings per share rose 4% to $1.62, and Adjusted EBITDA increased 7% to $223 million.
- For the nine months ended September 30, 2025, reported sales increased 3% to $2.81 billion, and core sales also increased 1%. Reported net income grew 16% to $318 million, and reported earnings per share increased 17% to $4.75. Adjusted earnings per share increased 7% to $4.48, and Adjusted EBITDA rose 8% to $624 million.
- The company returned $70 million to shareholders in Q3 2025 through share repurchases and dividends, bringing the year-to-date total to $279 million. AptarGroup ended September 2025 with $265 million in cash and short-term investments, $936 million in net debt, and a leverage ratio of 1.22.
- AptarGroup expects adjusted earnings per share for the fourth quarter of 2025 to be in the range of $1.20 to $1.28.
Oct 30, 2025, 9:01 PM
AptarGroup Reports Third Quarter 2025 Results
ATR
Earnings
Guidance Update
Dividends
- AptarGroup reported Q3 2025 sales of $961 million, a 6% increase (1% core sales growth) compared to the prior year period.
- For Q3 2025, reported net income increased 28% to $128 million, with reported earnings per share at $1.92 (up 30%) and adjusted earnings per share at $1.62 (up 4%).
- Year-to-date through September 30, 2025, reported sales reached $2.81 billion (up 3%), with reported EPS of $4.75 (up 17%) and adjusted EPS of $4.48 (up 7%).
- The company returned $70 million to shareholders in Q3 2025 through share repurchases and dividends.
- AptarGroup anticipates Q4 2025 adjusted earnings per share to be in the range of $1.20 to $1.28.
Oct 30, 2025, 9:00 PM
Quarterly earnings call transcripts for APTARGROUP.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more